Should everyone be taking Ozempic? Doctors say more people could benefit.

Novo Nordisk's Ozempic.
Should Ozempic be added to the water supply?
That is the kind of half-joking question that doctors kick around when a new class of drugs begins to help a big chunk of the population. Cardiologists used to quip about spiking water systems with cholesterol-reducing statins because of their ability to prevent heart attacks.
Now, Ozempic and others in the 'GLP-1" category of drugs are approaching that critical mass. They are showing promise for an ever-expanding list of diseases, beyond today's most common uses of weight loss and treating diabetes. Heart, kidney and liver diseases. Sleep apnea. Arthritis. Alzheimer's disease. Alcohol addiction. Even aging. Some of these are potential benefits that need further study.
'It is getting to the point of wondering what GLP-1 agonists aren't good for," pharmaceutical researcher and blogger Derek Lowe wrote in the academic journal Science last year.
If this trajectory continues, doctors say millions more people would benefit from them—maybe even one-third to a majority of adults.
But they also caution about use of the drugs in people who don't medically fit the bill because it could cause malnourishment. Doctors would have to figure out ways to guard against excessive weight loss in people who aren't overweight, perhaps putting them on special diets, said Dr. Scott Isaacs, an endocrinologist in Atlanta.
The drugs—which also include Wegovy, Mounjaro and Zepbound—mimic naturally occurring gut hormones such as GLP-1. The medicines promote production of insulin, which helps control blood-sugar levels in people with Type 2 diabetes. They suppress appetite and make people feel full faster when eating, helping overweight people lose many pounds.
In diabetes and obesity alone, the eligible patient population is huge. More than 100 million American adults—or 40%—have obesity. About 38 million have diabetes.
Many of the proven and potential benefits of the drugs cascade from their effect on obesity. Losing weight relieves sleep apnea. It takes pressure off the joints, helping with arthritis.
'If you treat obesity, all of the complications of obesity that we spend a lot of our time treating in medicine should get better," said Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine.
Eli Lilly's Zepbound and other GLP-1 drugs help control appetite and blood sugar by mimicking naturally occurring gut hormones.
But it also seems likely that some benefits are independent of weight loss, possibly because of anti-inflammatory effects of the drugs.
'The science is evolving very quickly in understanding how these medications affect so many organs and inflammation," said Dr. Robert Kushner, an obesity-treatment specialist at Northwestern University's Feinberg School of Medicine.
Doctors say GLP-1-type drugs may help with psoriatic arthritis, an autoimmune condition that causes joint pain and skin rashes, because of weight loss but also for their potential to reduce inflammation.
Susan Abernethy of North Cove, Wash., started taking Eli Lilly's diabetes drug Mounjaro in 2023 to help treat her psoriatic arthritis after older treatments weren't working as well.
The 58-year-old chief operating officer of a nonprofit credits Mounjaro with helping her lose weight and relieving her joint pain. She takes it along with Taltz, which is approved to treat psoriatic arthritis. Her insurance pays for the combination in part because she also has Type 2 diabetes.
'After about four years of not being able to run and do things, I've been able to do a couple of 5Ks again," she said. 'I can walk longer on the beach than before."
Lilly is studying the combination of Taltz and Mounjaro's main ingredient to treat psoriatic arthritis in a Phase 3 study, with hopes of seeking regulatory approval of the use if the study is successful.
Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a fatty-liver condition called metabolic dysfunction-associated steatohepatitis, or MASH, which is estimated to afflict about 15 million Americans.
A study published in the New England Journal of Medicine in April found that semaglutide, the main ingredient of Ozempic and Wegovy, improved the condition in patients.
Another area being considered: Alzheimer's disease. Researchers believe GLP-1s may have neuroprotective effects, slowing loss of brain volume. A small study in the U.K. last year found that Novo Nordisk's GLP-1 liraglutide slowed cognitive decline versus a placebo. Novo is conducting a Phase 3 trial of semaglutide in patients with early Alzheimer's.
Production of Novo Nordisk's Wegovy. If many more people are going to take GLP-1 drugs, more capacity is needed.
About 137 million American adults—more than half of the adult population—are eligible for treatment with the GLP-1 drug semaglutide, based on having Type 2 diabetes, meeting the threshold for excess body weight, or having established cardiovascular disease and excess weight, researchers estimated in a paper published in JAMA Cardiology last year. In comparison, about 82 million U.S. adults are eligible for statins.
But only a fraction of those eligible are currently taking a GLP-1 drug—about 8.3 million in the U.S. this year, TD Cowen estimated. The percentage of the eligible population taking a GLP-1 outside the U.S. is even smaller.
'Global uptake of weight-loss drugs is minuscule relative to the addressable market," TD Cowen analysts wrote in a research note.
Still, some people clearly shouldn't take the drugs. 'I do believe that a large percent of the population, but not everybody, is going to be able to get some benefit," Aronne said.
People with a history of a type of thyroid cancer, or with certain head and neck tumors, shouldn't take them because earlier studies showed the drugs caused those types of tumors in rats.
Some doctors are reluctant to prescribe them to people with a history of pancreatitis because some patients taking the drugs have developed severe cases of that condition. And some doctors shy away from prescribing them for cosmetic weight loss when no other medical conditions are present.
Use of the drugs will surely grow. Morgan Stanley analysts estimate that by 2035, the number of Americans using a GLP-1 for obesity alone will rise to about 29 million. But even that would only represent 20% of the eligible obesity population.
That is because anti-obesity drugs are expensive. List prices are over $1,000 a month, many insurance plans don't cover them and even manufacturer-discounted prices are still several hundred dollars a month.
Tolerability and manufacturing capacity of the drugs might also be issues. Some patients stop taking the drugs because they suffer unpleasant gastrointestinal side effects. And two main manufacturers, Lilly and Novo, only recently resolved drug shortages by increasing production. But they are still far from reaching enough capacity to supply significantly bigger percentages of both current and future eligible populations.
More studies and better drugs could help boost the treatment rate. Companies are developing newer GLP-1s that could deliver greater weight loss, and pill versions that might be appealing to patients who don't like getting shots.
Write to Peter Loftus at Peter.Loftus@wsj.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Time of India

24 minutes ago

• Time of India

Is Samantha Ruth Prabhu's 'meal sequencing' hack the real deal for blood sugar? Expert breaks it down

When actress Samantha Ruth Prabhu revealed how rearranging her meals stabilized her blood sugar, fans began calling it a 'game‑changer.' But is this trending 'meal sequencing' diet hack truly effective—or just another wellness fad? Upon discovering erratic glucose spikes despite clean eating, Samantha turned detective with her tracking device. She noticed that eating her plate in a specific order—vegetables first, protein next, carbs last—helped smooth out her readings. Experts dubbed this method 'food sequencing,' and suddenly, it was trending among health circles. The Science Behind the Sequence The concept isn't new. UCLA Health explains that consuming fibrous vegetables and protein before refined carbs can slow carbohydrate absorption and prevent sharp insulin surges. Particularly for those with Type 2 diabetes, research supports the stability this approach provides. — BrainMDHealth (@BrainMDHealth) Control Sugar, Control Disease Refined carbs like white rice and sugary snacks trigger fast blood sugar spikes. Immune‑boosting whole foods—think beans, legumes, leafy greens—release energy gradually and blunt glucose surges. A 2022 study cited by Nadeau even linked eating veggies first to improved HbA1C levels in diabetes patients over five years. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like AC Installation & Repair from Certified Pros Search7 Learn More The order of eating also influences fullness. Protein-first meals boost GLP‑1, a satiety hormone, delaying stomach emptying. Fiber further enhances this effect, reducing overeating. As registered dietitian Jamie Nadeau notes, natural anti‑inflammatory foods help manage chronic low‑grade inflammation that often accompanies poor diets. Expert's Verdict: Effective—but Not a Silver Bullet Acoording toa report from USA Today, dietitian Jamie Nadeau cautions against overselling the hack. 'Generally there isn't enough research to support this being a solid strategy,' she tells us. While meal sequencing may aid blood sugar control , it doesn't replace holistic diet and lifestyle habits. 'No quick fixes,' she reminds readers, especially those hoping for a shortcut to 'nature's Ozempic.' You Might Also Like: Samantha Ruth Prabhu shares one simple trick that fixed her spikes in blood sugar levels UCLA Health supports this view, adding that while meal timing can help, the strongest health gains still come from balanced eating, activity, and mindful nutrition. Should You Try It? If pairing your fork and knife in a veggie‑first order sounds manageable, go ahead. But experts stress that this technique is a small piece of a much larger wellness puzzle. The core pillars remain consistent: whole grains, lean proteins, healthy fats, and lifestyle balance. So next time you fill your plate, consider this question: Could a little shift in comfort food order help you age better, feel fuller, and keep blood sugar in check? Maybe so—but only when it joins forces with a well-rounded diet and healthy habits. You Might Also Like: Want to live longer? Forget expensive experiments; longevity doctor reveals simple secrets to a healthier, happier life

Mint

an hour ago

• Mint

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

CagriSema shows mild-to-moderate side effects in trials Researcher sees benefit to additional weight-loss options Novo Nordisk plans regulatory filing for CagriSema in early 2026 June 22 (Reuters) - Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen. The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients. In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group. "Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters. The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group. Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target." CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin. The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said. Eli Lilly's tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks. Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said. Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026. "We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes. Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said. (Reporting By Deena Beasley, Editing by Franklin Paul)

Business Standard

10 hours ago

• Business Standard

IVF players on expansion mode in smaller towns as fertility rates go down

Major in-vitro fertilisation (IVF) chains are expanding into untapped Tier 2 and 3 cities, driven by improved healthcare infrastructure, growing acceptance of fertility treatments, and rising disposable incomes in smaller urban centres. Birla Fertility and IVF, which currently operates around 30 centres in Tier 2 and 3 cities, plans to open at least 15 to 16 more centres in FY26, two-thirds of which will be in smaller towns. Nova IVF, which derives 40 per cent of its revenue from such cities, is exploring expansion in 15 locations including Haldwani, Jamnagar and Meerut. Indira IVF, the country's largest infertility chain, has also announced plans to enter over 25 Tier 3 cities by FY27. Explaining the rationale, Shobhit Agarwal, Chief Executive Officer (CEO) of Nova IVF Fertility, said, 'With one in six couples experiencing infertility in India, there is a need for fertility chains to expand to cater to couples battling infertility.' A recent United Nations Population Fund (UNFPA) report highlighted that India's total fertility rate (TFR) has fallen to 1.9 births per woman — below the replacement level of 2.1. The report echoes findings from the National Family Health Survey (NFHS)-5, which pegged India's TFR at 2.0 births per woman for 2019–21. The NFHS-5 also found the fertility rate had declined more significantly in rural areas, where it stood at 2.1 — down from 3.7 in NFHS-1 (1992–93). In urban areas, it fell to 1.6 from 2.7 in the same period. While infertility is not the sole factor behind the falling TFR, experts suggest infertility cases are expected to rise beyond Tier 1 cities, fuelled by stress-related lifestyle diseases and climate change. Industry insiders say IVF players are already witnessing increased demand for infertility treatment from Tier 2 and 3 cities. Abhishek Aggrawal, CEO of Birla Fertility and IVF, told Business Standard that more than 50 per cent of the company's annual IVF cycles are conducted in cities such as Siliguri, Varanasi and Prayagraj. 'While there is a rising segment in metros, with IVF chains receiving queries from women for procedures like egg freezing to delay parenthood, Tier 2 cities are providing an opportunity to tap less penetrated, high-potential markets,' he said. Agarwal added that many couples from Tier 2 regions find it difficult to travel to larger cities for fertility treatment, as the cost of travel, accommodation and lost wages makes the process financially burdensome. 'With expansion, we are bringing standardised fertility treatment to their home towns, with the best clinical acumen and embryologists,' he said. This model, he added, is affordable and avoids additional hassle. India currently performs around 200,000 to 250,000 IVF cycles annually, and the market is projected to grow to 400,000 cycles by 2030, with smaller cities expected to account for a substantial share of this growth. Aggrawal noted that to meet this growing demand, IVF chains are also focusing on building awareness to ensure fertility care is both accessible and better understood by those in need.